---
title: "光啓科學減持光啓技術  變現 1.86 億人民幣"
description: "光啓科學公佈，12 月 2 日，於公開市場出售光啓技術合共 389.37 萬股，每股平均價 47.76 元人民幣，所得淨額 1.86 億人民幣，將用作再融資及一般營運資金。估計出售收益 3,030 萬人民幣。完成後，集團將繼續持有光啓技術 4,079.99 萬股。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/268290174.md"
published_at: "2025-12-02T15:39:57.000Z"
---

# 光啓科學減持光啓技術  變現 1.86 億人民幣

> 光啓科學公佈，12 月 2 日，於公開市場出售光啓技術合共 389.37 萬股，每股平均價 47.76 元人民幣，所得淨額 1.86 億人民幣，將用作再融資及一般營運資金。估計出售收益 3,030 萬人民幣。完成後，集團將繼續持有光啓技術 4,079.99 萬股。

光啓科學 (00439.HK) 公佈，12 月 2 日，於公開市場出售光啓技術 (002625.SZ) 合共 389.37 萬股，每股平均價 47.76 元人民幣，所得淨額 1.86 億人民幣，將用作再融資及一般營運資金。估計出售收益 3,030 萬人民幣。完成後，集團將繼續持有光啓技術 4,079.99 萬股。

### Related Stocks

- [02913.HK - 恆益控股股權](https://longbridge.com/zh-HK/quote/02913.HK.md)
- [00439.HK - 瀚源控股](https://longbridge.com/zh-HK/quote/00439.HK.md)
- [002625.CN - 光啟技術](https://longbridge.com/zh-HK/quote/002625.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| KuangChi Science Renames as Genesis Scale Holdings | KuangChi Science Renames as Genesis Scale Holdings | [Link](https://longbridge.com/zh-HK/news/271000832.md) |
| Table-Non-competitive bids for U.S. 2-year notes | Feb 24 (Reuters) - Below are results from non-competitive bids on U.S. 2-Year Notes Security 2-year notes Issue Date Mar | [Link](https://longbridge.com/zh-HK/news/276771657.md) |
| Graduate recruitment crisis: Here’s who is actually still hiring in 2026 | The job market for recent graduates in 2026 is challenging, with hiring slowdowns attributed to cost pressures, economic | [Link](https://longbridge.com/zh-HK/news/276857149.md) |
| Olympics-IOC hails 'incredible' Milano Cortina Games despite string of obstacles | The Milano Cortina Games were hailed as a success by the IOC despite facing numerous challenges, including tight deadlin | [Link](https://longbridge.com/zh-HK/news/276534545.md) |
| Sunshine Lake Pharma Wins NMPA Nod to Trial First China-Developed Nipah Virus Antibody | Sunshine Lake Pharma has received approval from China's Center for Drug Evaluation to begin clinical trials for HEC-648  | [Link](https://longbridge.com/zh-HK/news/276716153.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。